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ctotal of 828 abstracts were submitted in the various
yocardial ischemia and infarction categories. Of these, 297
ere accepted for presentation. The presented abstracts may
e grouped into seven topical categories.
. Prevention of coronary heart disease (CHD)
. Risk prediction for CHD
. Pharmacologic treatment for ST-segment elevation
myocardial infarction (STEMI)
. Reperfusion treatment for STEMI
. Advances in cell therapy for CHD
. Quality management and improvement in myocardial
infarction (MI)
. Miscellaneous topics
his article summarizes the most significant presentations.
REVENTION OF CHD
ole of aspirin and vitamin E in preventing coronary
vents in women. Paul Ridker and Stacy Buring presented
he results of the Women’s Health Study Research Group
andomized trial of primary prevention of CHD in 39,876
nitially healthy female health professionals age 45 years
1). Subjects were randomized in a double factorial random-
zation scheme to 100 mg of aspirin every other day versus
lacebo and 600 mg vitamin E every other day versus
lacebo. Follow-up was 10.1 years. The end points were
ardiovascular mortality, nonfatal MI, and nonfatal stroke.
he aspirin arm of the trial was positive and the vitamin E
rm was negative. Because this was a very healthy popula-
ion, the overall end point event rate was small at 2.5% over
10-year observation period. Aspirin reduced the end point
vent rate by 9%, which was not statistically significant (p
.13). The reduction was leveraged by a significant reduc-
ion in the rate of ischemic stroke (relative risk  0.76; p 
.009). There was no effect on all-cause mortality or
ardiovascular death. This study demonstrates a modest
rotective effect of aspirin, even in a low-risk population,
nd confirms the lack of effectiveness of vitamin E.
lood pressure (BP)-lowering strategy revisited. Peter
ever presented the findings of the (Anglo-Scandanavian
ardiac Outcomes Trial (ASCOT) blood pressure-
owering arm (2). This trial compared two different phar-
acologic strategies for lowering BP (amlodipine  perin-
opril vs. atenolol  benzoflumethazide) in 19,257
ypertensive men and women. The protocol treated patients
o a BP140/90 mmHg for non-diabetics and 130/80 mm
g for diabetics. Amlodipine or atenolol were startedoFrom the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.nitially and perindopril or benzoflumethazide were added if
arget BP was not achieved with a single drug. Follow-up
as 5.1 years. End points were cardiovascular mortality and
onfatal MI. The majority of patients required both drugs
o achieve target BP. The trial was stopped prematurely by
he safety committee because of the emergence of superior-
ty in the amlodipine/perindopril group. The primary end
oint was reduced by 10% from 4.6% to 4.1%. Other
ultiple cardiovascular end points were reduced in the
mlodipine/perindopril group (stroke 30%, all coronary
vents 13%, all cardiovascular events and procedures 16%,
ardiovascular mortality 16%). The trial demonstrates the
uperiority of the amlodipine/perindopril strategy. The
ifference between the strategies was not due to differences
n BP because both groups achieved the same target BP
evels. Thus, the difference must be due to the different drug
lasses used. Because the majority of patients received both
rugs, one cannot determine whether one of the drugs in
he trial arm pair was predominantly responsible for the
ifference.
ggressive low-density lipoprotein (LDL) lowering. John
aRosa presented the results of the Treating to New
argets (TNT) trial. Patients with clinically evident coro-
ary disease were enrolled (n  10,002) (3). Eligibility
equired that subjects achieve an LDL below 130 mg/dl on
0 mg of atorvastatin. Eligible subjects were then random-
zed between continuing 10 mg of atorvastatin and advanc-
ng to 80 mg of atorvastatin. Patients were followed until
he design-required number of end point events (cardiovas-
ular mortality, nonfatal MI, resuscitated cardiac arrest, or
troke) had been accumulated (five years). The 10 mg
torvastatin group achieved a mean LDL of 100 mg/dl,
hereas the mean LDL for the 80 mg atorvastatin group
as 80 mg/dl. The frequency of end point events was
educed in the 80 mg atorvastatin group (10.0% vs. 12.2%;
 0.002). There was no difference between the two groups
n the frequency of statin-related side effects. This study
alidates the concept that, with LDL cholesterol, lower is
etter.
HD RISK PREDICTION
wo studies were presented that endeavored to refine the
bility to predict future coronary risk.
ultimarker approach to risk prediction. Christopher
rant, representing the Women’s Ischemia Syndrome Eval-
ation (WISE) team, investigated a high-risk population of
95 women who were being evaluated for suspected myo-
ardial ischemia (4). The population had a high prevalence
f traditional coronary risk factors. They were further risk
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June 7, 2005:12B–6B ACC 2005 Annual Session Highlightstratified by markers of inflammation—high-sensitivity
-reactive protein (hs-CRP), interleukin-6, and serum
myloid antigen.
The women were followed for a mean of 3.6 years with
nd points of all-cause death, hospitalization for MI,
ongestive heart failure, stroke, or other vascular events. The
nnual risk of an end point event increased progressively if
wo or more abnormal markers were present (0 or 1 marker
1.90%; 2  3.68%; 3  5.5%). These findings are
onsistent with the importance of inflammatory markers as
redictors of vascular risk independently of other risk
actors.
nflammation and hyperglycemia. Kausik K. Ray, repre-
enting the Thrombolysis In Myocardial Infarction (TIMI)
nvestigators, conducted a pooled analysis of the patients
nrolled in four TIMI trials (5). Patients with acute coro-
ary syndromes were categorized by the presence or absence
f diabetes, and within diabetics, by tertiles of glucose level.
atients were also characterized by levels of hs-CRP.
iabetic patients, as a group, had higher levels of hs-CRP
han non-diabetics. End points were death or MI over 10
onths. Both diabetes and hs-CRP were predictive of
vents, with diabetes being the stronger predictor. Non-
iabetics with low hs-CRP levels had an 18% event rate
ompared with 33% for diabetics with elevated hs-CRP
evels. The worst outcomes were in diabetics with elevated
s-CRP levels whose random glucose was in the top tertile.
his study demonstrates, once again, that diabetes is a
owerful adverse risk factor and the hs-CRP level adds
ndependent incremental risk prediction.
HARMACOLOGIC TREATMENT OF STEMI
tudies of both classical as well as novel therapeutic ap-
roaches to the treatment of STEMI were presented. The
lassical approaches involved refinements of antiplatelet and
eta-blocker therapy. The novel approaches examined an
ld and a new treatment strategy.
Clopidogrel was studied in two randomized STEMI
rials, both of which demonstrated benefit for adjunctive
oncomitant clopidogrel therapy at the time of presentation
ith STEMI.
lopidogrel as an adjunct to thrombolysis. Marc Saba-
ine, representing the TIMI-28 study group, presented the
esults of the Clopidogrel as Adjunctive Reperfusion Ther-
py (CLARITY) trial (6). This trial randomized 3,496
atients who had undergone intravenous fibrinolysis for
TEMI to an antiplatelet regimen of aspirin alone com-
ared with aspirin plus a 300-mg load of clopidogrel
ollowed by a daily dose of 75 mg. Patients subsequently
nderwent angiography at a median of 3.5 days after
brinolysis. Efficacy end points included death, recurrent
I, or an occluded infarct artery. The safety end point was
IMI major bleeding. The primary end point through the
ime of angiography was reduced from 21.7% to 15.0%
odds ratio 0.64; p  0.001) and was leveraged predomi- pantly by greater infarct artery patency at the time of elective
ngiography. The frequency of TIMI major bleeding was
imilar in both treatment groups, although TIMI minor
leeding was slightly, but not statistically, significantly
ncreased (1.0% vs. 0.5%; p  0.17) in the clopidogrel
roup. This study demonstrated a benefit of clopidogrel
herapy in patients who do not receive prompt invasive
valuation and treatment.
lopidogrel as an adjunct to aspirin. Clopidogrel was also
tudied as an adjunct to standard therapy with aspirin in
atients with STEMI who mostly did not receive subse-
uent invasive therapy (7). Zhenming Chen reported the
esults of the Clopidogrel and Metoprolol in Myocardial
nfarction (COMMIT/CCS2) study, which enrolled
6,000 patients presenting with STEMI at 1,250 hospitals
n China. The patients were randomized to receive aspirin
lone or aspirin plus 75 mg of clopidogrel per day (no
oading dose) for 30 days. Fifty-two percent of the patients
eceived thrombolytic therapy. The end point was a com-
osite of death, nonfatal re-infarction, and stroke. The
lopidogrel group had a 9% reduction in the end point
9.3% vs. 10.1%; p  0.002) at 30 days. The primary end
oint difference was driven mainly by a reduction in mor-
ality (7.3% vs. 8.1%; p  0.03).
pstream administration of abciximab. Jochen Goedicke
resented a meta-analysis of six clinical trials of primary
ercutaneous coronary intervention (PCI) for STEMI com-
aring the outcomes of patients who received abciximab
efore angiography (upstream) compared with receiving it
t the time of PCI (8). The primary end point was a
omposite of death, re-infarction, and target vessel revascu-
arization at 30 days. Upstream abciximab patients received
he drug an average of 50 min before PCI compared with 5
in in the non-upstream group. Infarct artery patency at
he time of angiography was greater in the upstream group
43% vs. 29%; p  0.001). This resulted in a non-
tatistically significant decrease in the frequency of the
omposite end point (7.3% vs. 9.7%) and a non-statistically
ignificant decrease in the frequency of death (2.7% vs.
.7%). There was no difference in the frequency of major
leeding (3.5% vs. 3.8%). This study indicates that upstream
dministration of abciximab appears to improve outcomes in
rimary PCI for STEMI.
arly administration of metoprolol. The COMMIT/
CS2 trial was a two-armed multifactorial design trial. The
econd arm was a randomization to metoprolol versus
lacebo (9). Patients with STEMI who were randomized to
etoprolol therapy received three 5-mg intravenous boluses
f metoprolol followed by a daily oral dose of 200 mg for 30
ays. The end point events were the same as in the
lopidogrel arm of the trial. The results of this trial were
ore complex to interpret. Overall, there was no effect on
ortality (metoprolol 7.7% vs. placebo 7.8%). However,
etoprolol reduced the frequency of ventricular fibrillation
2.5% vs. 3.9%). There was an increased mortality in
atients who presented with hemodynamic instability that
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ACC 2005 Annual Session Highlights June 7, 2005:12B–6Bffset a trend toward improved mortality in non-
emodynamically compromised patients. The conclusion
rom the trial was that metoprolol appeared to be beneficial
n patients without hemodynamic compromise, but that it
as likely detrimental to compromised patients.
lucose-insulin-potassium (GIK) revisited. There has
een a 30-year controversy over whether administration of a
IK solution is beneficial in the early phases of STEMI.
he Glucose Insulin Potassium Study (GIPS I) had sug-
ested a possible benefit of high-dose GIK in Killip class I
atients. Jorik Timmer presented the results of the GIPS II
rial, which was confined to high-dose GIK in Killip class I
TEMI patients (10). End points were death at 30 days,
nzymatic infarct size, and left ventricular (LV) function.
he trial was stopped early by the Data Safety and Moni-
oring Committee because of lack of effect on enzymatic
nfarct size and a non-significant trend toward increased
ortality (2.9% vs. 1.8%; p  0.26) in the GIK treatment
roup. Thus, the findings of the GIPS I trial were not
onfirmed and there seems to be little rationale for GIK
herapy for STEMI.
atrix metalloproteinase (MMP) inhibition. W. Doug-
as Weaver presented a randomized trial assessing the
fficacy of acute treatment with PG116800, a MMP inhib-
tor, with the goal to prevent ventricular remodeling after
TEMI (11). The trial enrolled 253 patients undergoing
rimary PCI for STEMI. The population had major MIs
80% anterior, LV ejection fraction 15% to 40%). End
oints were a change in LV ejection fraction, a change in
erum pro-brain natriuretic peptide, a change in hs-CRP,
nd a composite clinical end point of new or worsening
ongestive heart failure, hospitalization for congestive heart
ailure, or death. Analysis of the data revealed no detectable
ffect of the treatment, indicating that MMP inhibition
oes not appear to affect remodeling or outcome after
TEMI.
EPERFUSION TREATMENT OF STEMI
any studies assessing refinement of reperfusion treatment
or STEMI were presented. The predominant theme was to
e-evaluate the 90-min door-to-balloon time standard.
oes a 90-min door-to-balloon time matter? William
. O’Neill presented the results of a pooled analysis of four
rials of PCI for STEMI (Enhanced Myocardial Efficacy
nd Removal by Aspiration of Liberated Debris [EMER-
LD], COOL MI feasibility trial [COOL], Acute Myo-
ardial Infarction HyperOxemia Trial [AMI-HOT], Intra-
ascular Cooling Adjunctive to Primary Coronary
ntervention [ICE-IT]) (12). A total of 1,355 patients were
vailable for analysis and were stratified by symptom onset-
o-door time and door-to-balloon time. Outcome variables
ere death at 30 days, major cardiac adverse events at 30
ays, and infarct size by sestamibi imaging. Both symptom
nset-to-balloon time (p  0.025) and door-to-balloon
ime (p 0.0001) were independently associated with death St 30 days. Each outcome variable showed a graded rela-
ionship with door-to-balloon time up to 90 min, after
hich the relationship appeared to flatten.
nterhospital transfer delay and mortality of STEMI. Giu-
eppe DeLuca examined outcomes in 616 patients who were
ransferred to a single hospital for primary PCI for STEMI
13). The institution’s mean door-to-balloon time was 38
in. Patients were stratified by the time delay between
rrival at the first hospital and arrival at the referral hospital.
nd points were death at one year, myocardial blush grade,
nd serum lactate dehydrogenase (LDH) at 48 h after the
CI. Statistically significant associations were found for
DH at 24 h (p  0.049) and death at 1 year (p  0.01).
here was a strong trend toward improving myocardial
lush grade with shorter delay times. The association with
eath was particularly strong (30 min  3.2%; 30 to 59
in  6.4%; 60 to 89 min  6.2%; 90 min  12.1%).
Both the previously cited studies strongly reaffirm the
mportance of minimizing time to reperfusion in the man-
gement of STEMI.
Two other studies examined the National Registry of
yocardial Infarction (NRMI) to focus on strategies to
horten door-to-balloon time.
oor-to-balloon time: where can we improve? Elizabeth
radley presented an analysis of 13,387 patients from the
RMI registry who received PCI for STEMI at 340
articipating hospitals (14). Hospitals were separated into
wo groups: median door-to-balloon time 90 min and
edian door-to-balloon time 120 min. Door-to-balloon
ime was fractionated into three segments: door-to-
lectrocardiography time; electrocardiography-to-lab time;
nd lab-to-balloon time. Each segment of the overall
oor-to-balloon time was longer in the poorer performing
ospitals than in the top performing hospitals. This analysis
ndicates that the determinants of door-to-balloon time are
ultifactorial and that institutions need to focus on improv-
ng each aspect of the process.
elationship between symptom onset-to-door time and
oor-to-balloon time. Robert L. McNamara presented an
nalysis of 29,688 patients from the NRMI registry who
eceived primary PCI for STEMI (15). Patients were
tratified by symptom onset-to-door time and those groups
ere analyzed for outcome according to door-to-balloon
ime. The principal outcome variable was risk-adjusted
eath at 30 days. Interestingly, the relationship between
oor-to-balloon time and death was stronger than the
elationship between symptom-to-door time and death.
here was a strong relationship between increasing risk of
eath and increasing door-to-balloon time both in patients
ith a symptom-to-door time of 2 h and 2 h. Linear-
zing the mortality rates indicated that each incremental
0-min delay in door-to-balloon time increased mortality
isk by 0.3%.
echanical reperfusion for STEMI after 12 h. It is
ogical to ask whether there is a point in the evolution of an
TEMI beyond which reperfusion no longer provides
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June 7, 2005:12B–6B ACC 2005 Annual Session Highlightsenefit. Albert Schömig presented a randomized trial from
ine centers in Germany, Italy, and Austria, in which 365
atients with STEMI, who presented to a PCI center more
han 12 h after symptom onset and were not experiencing
ngoing ischemia or heart failure, were randomized to
mergency PCI or medical therapy (16). End points were
nfarct size by sestamibi imaging and a composite of death,
ecurrent MI, and stroke at 30 days. The invasive strategy
educed the scintigraphic estimate of infarct size from 13%
o 8% of the LV (p  0.0002). There were trends favoring
he invasive strategy in both death at 30 days (invasive 
%; conservative  4%; p  0.21) and in the combination
f death and recurrent MI (invasive  4%; conservative 
%; p  0.49). These findings indicate that late reperfusion
ppears to offer incremental benefit over conservative
herapy.
ELL THERAPY FOR MI
here has been considerable interest in the use of various
ypes of stem cells to repair both acute and old MIs. These
rials are still in their infancy and many complex problems
xist.
arly intracoronary autologous bone marrow stem cells
or STEMI. Stefan Janssens presented a randomized trial
f autologous bone marrow stem cells versus placebo ad-
inistered into the infarct artery 24 h after PCI for STEMI
17). End points were global LV contractile function by
agnetic resonance imaging, changes in regional contrac-
ility by stress echocardiography, and C11 palmitate meta-
olic imaging, all determined four months after treatment.
he results were disappointing in that there was no detect-
ble effect on LV contractile function at four months,
lthough the estimate of metabolic infarct size was slightly
educed in the treatment group at four months.
urgically administered skeletal muscle myoblasts for
schemic cardiomyopathy. Nabil Dib presented the results
f surgical direct myocardial injection of skeletal muscle-
erived myoblasts at the time of bypass surgery in 22
atients undergoing surgical revascularization (18). There
as no control group. There was evidence of viability in the
reated myocardial regions both by positron emission tomo-
raphic scanning and by magnetic resonance imaging. Two
atients developed non-sustained ventricular tachycardia.
hese findings appear to indicate that injected autologous
yoblasts survive when injected into regions of old MI.
oncern remains about the arrhythmic potential of this
reatment and the lack of demonstrated efficacy on ventric-
lar function.
ercutaneously delivered skeletal muscle myoblasts for
ld Q-wave MI. Patrick Serruys reported the results of
atheter injection of skeletal muscle-derived myoblasts into
reas of old Q-wave MI (19). There was no control group.
ecause of previous experience with ventricular tachycardia,
prophylactic implantable cardioverter-defibrillator wasmplanted in each patient. Observations were stress echo- eardiography at 3, 6, and 12 months after the procedure.
wo patients died of arrhythmia during the observation
eriod. There were non-significant trends toward improved
V ejection fraction (baseline  34.4%; 12 months 
6.6%; p  0.26), regional resting wall motion score index
baseline  3.0; 12 months  2.7; p  0.049), and
obutamine stress wall motion score index (baseline  2.8;
2 months  2.5; p  0.07).
UALITY IMPROVEMENT FOR MI MANAGEMENT
uaranteeing quality of care using Guidelines Applied in
ractice (GAP). Smit Vasaiwala presented an analysis of
he efficacy of reliably applying American College of Car-
iology (ACC) guidelines to the management of acute
oronary syndromes (20). He studied the outcomes of
atients presenting to a single academic health center with
cute coronary syndromes. A total of 2,016 were admitted
efore the institution activated the ACC GAP project that
ystematizes care of patients with acute coronary syndromes.
total of 618 patients were admitted after the GAP project
as started. End points were adherence to guidelines;
evelopment of heart failure, stroke, or death while in the
ospital; and bleeding while in the hospital. Application of
he GAP project led to dramatic improvements both in
onsistency of care (appropriate use of angiotensin-
onverting enzyme inhibitors, beta-blockers, and statins)
nd in outcomes. Heart failure episodes were reduced from
2.9% to 3.6% (p  0.001). Stroke was reduced from 1.1%
o 0.2% (p  0.02). There was a non-significant reduction
n death from 4.8% to 4.2% (p 0 .53). Major bleeding was
educed dramatically from 7.9% to 1.8% (p  0.001). This
tudy confirmed the value of a consistent rigorous approach
o care following the ACC guidelines.
ISCELLANEOUS TOPICS
afety of cyclooxygenase (COX)-2 inhibitors in coronary
rtery bypass grafting (CABG) and other surgery. An-
rew Whelton presented an analysis of the use of COX-2
nhibitors as analgesics for postoperative pain after CABG
nd non-cardiac surgery (21). A total of 1,671 patients
ndergoing CABG and 1,062 non-cardiac surgical patients
ere randomized to an intravenous load of parecoxib on
ostoperative day 1 followed by oral valdecoxib versus
lacebo. All CABG patients received aspirin. Outcome
ariables were MI or stroke, gastrointestinal bleeding, and
ound complications. The frequency of MI or cerebrovas-
ular accident increased in CABG patients who received the
arecoxib/valdecoxib versus placebo (2.0% vs. 0.5%; p 
.033). However, there was no difference in event rates in
on-cardiac surgery patients (1.0% in both groups). This
tudy suggests that in patients undergoing CABG, COX-2
nhibition increases the risk of thrombotic complications.
omegranate juice! Michael Sumner presented a random-
zed trial of 45 patients with stable coronary disease and LV
jection fraction 30% comparing treatment with a daily
d
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ACC 2005 Annual Session Highlights June 7, 2005:12B–6Bose of 240 ml of pomegranate juice to placebo (22).
omegranate juice contains large quantities of polyphenolic
ntioxidants. The outcome variable was a change in the
egree of stress-induced ischemia, using a quantitative
coring system, after three months of treatment. The
lacebo group’s mean score increased by 1.2, whereas the
omegranate juice group’s mean score decreased by 0.7 (p
.05). This study suggested that long-term treatment with
ntioxidants is beneficial for reducing the severity of stress-
rovocable ischemia.
eprint requests and correspondence: Dr. John W. Hirshfeld,
r., Cardiac Catheterization Laboratory, 9.119 Founders Pavilion,
niversity of Pennsylvania Medical Center, 3400 Spruce Street,
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